wilms tumor/diarreia

O link é salvo na área de transferência

Escolha o tipo de classificação

12 resultados

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE The three-drug combination of melphalan (M), etoposide (E), and carboplatin (C) followed by autologous stem-cell (ASC) rescue has been evaluated prospectively by the French Society of Pediatric Oncology (SFOP) in pediatric high-risk recurrent (HRR) Wilms' tumor (WT) patients with

Wilms' tumor, male pseudohermaphroditism and glomerulonephritis: the Drash syndrome. First case report in Thailand and review the literatures.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The Drash syndrome, the first case in Thailand is reported. The patient had male pseudohermaphrodite, Wilms' tumor of the left kidney and mesangial proliferative glomerulonephritis. Metastasis of Wilms' tumor was noted in the liver, omentum, pelvic peritoneum and vertebral body. Chemotherapy

Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms' tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant therapy administered concurrently with standard treatments in

Clinico-immunological response to intratumoral versus intravenous neoadjuvant chemotherapy in advanced pediatric solid malignancies.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND There is minimal literature on the use of intralesional chemotherapy in the pediatric age group. We undertook this present study to evaluate the two modalities (intratumoral and intravenous) of giving chemotherapy in terms of toxicity of chemotherapy, hematological parameters, efficacy of

[Xanthogranulomatous pyelonephritis: presentation of an unusual case].

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Xanthogranulomatous pyelonephritis is a morphologically and clinically unique manifestation of chronic pyelonephritis with the formation of pus or granulomas. The most frequent predisposing factors for the development of xanthogranulomatous pyelonephritis are urinary obstruction (e. g.,

A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine, temozolomide and bevacizumab in children with refractory solid tumors. METHODS The study design included two dose levels (DL) of irinotecan given

Hemolytic uremic syndrome associated with Denys-Drash syndrome.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The Denys-Drash syndrome is defined by the occurrence of combinations of pseudohermaphroditism, nephrotic syndrome with diffuse mesangial sclerosis, Wilms' tumor, and constitutional mutations in the WT1 suppressor gene. Most patients develop end-stage renal failure. Atypical hemolytic uremic

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. METHODS Gefitinib (150, 300, 400, or 500 mg/m2) was

Cadaveric renal transplants in children under 6 years of age.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Thirty-nine cadaveric renal allografts were performed in 28 children under 6 years of age. Common primary renal diseases were glomerulonephritis, dysplasia/hypoplasia, and reflux/obstructive nephropathy. After a mean follow-up of 40 months of patients with surviving grafts, 19 patients had

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS Patients received cabozantinib tablets on a

Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Background Although the survival of pediatric cancer has increased dramatically in the last decades, the survival of refractory, relapsed, and metastatic cases is still dismal. The combination of irinotecan and temozolomide has shown activity against refractory/relapsed pediatric solid tumors.

Junte-se à nossa
página do facebook

Herbal & Natural Medicine

O mais completo banco de dados de ervas medicinais apoiado pela ciência

Funciona em 55 idiomas
Curas herbais apoiadas pela ciência
Reconhecimento de ervas por imagem
Mapa GPS interativo - marcar ervas no local (em breve)
Leia publicações científicas relacionadas à sua pesquisa
Pesquise ervas medicinais por seus efeitos
Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas